Table 2 Treatment-related adverse events (TRAEs)

From: A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer

 

Any Grade

Grade 3

Grade 4

Event

N

%

N

%

N

%

Any TRAEs

42

97.7

33

76.7

2

4.7

Hematologic

  Neutrophil count decreased

20

46.5

17

39.5

1

2.3

  Anemia

14

32.6

7

16.3

0

0

  Platelet count decreased

7

16.3

3

7

0

0

  Febrile neutropenia

5

11.6

4

9.3

0

0

Non-hematologic

  Anorexia

17

39.5

2

4.7

0

0

  Nausea

14

32.6

0

0

0

0

  Creatinine increased

13

30.2

2

4.7

0

0

  Diarrhea

13

30.2

1

2.3

0

0

  Hand-foot syndrome

10

23.3

0

0

0

0

  Oral mucositis

10

23.3

1

2.3

0

0

  General weakness

8

18.6

1

2.3

0

0

  Peripheral neuropathy

8

18.6

0

0

0

0

  Abdominal pain

6

14

0

0

0

0

  Fever

6

14

0

0

0

0

  Hypoalbuminemia

2

4.7

1

2.3

0

0

  Hyperkalemia

2

4.7

2

4.7

0

0

  Tinnitus

2

4.7

0

0

0

0

  Thromboembolic event

2

4.7

0

0

1

2.3

Immune-related

  Hypothyroidism

5

11.6

0

0

0

0

  Allergic reaction

4

9.3

1

2.3

0

0

  Pruritus

4

9.3

0

0

0

0

  Colitis

3

7

3

7

0

0

  Adrenal insufficiency

2

4.7

0

0

0

0

  Hyperglycemia

2

4.7

0

0

0

0

  Skin rash

2

4.7

0

0

0

0

  1. One patient died from Grade 5 pneumonia related to disease progression.